# NeoVas Bioresorbable Coronary Scaffold Registry Study

Study · id `cardio:ct-nct02305472` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02305472](<https://clinicaltrials.gov/study/NCT02305472>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02305472

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 825 participants.

## Technical summary

Registry record NCT02305472. Allocation not applicable; no masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2017-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 825 participants (planned count; ClinicalTrials.gov record NCT02305472, source copy `cardio:ctgov-nct02305472-2017-03-09`, retrieved 2026-10-26)
- Start date: 2014-11 (registry gives no type) (ClinicalTrials.gov record NCT02305472, source copy `cardio:ctgov-nct02305472-2017-03-09`, retrieved 2026-10-26)
- Primary completion: 2017-09 (anticipated) (ClinicalTrials.gov record NCT02305472, source copy `cardio:ctgov-nct02305472-2017-03-09`, retrieved 2026-10-26)
- Completion: 2020-09 (anticipated) (ClinicalTrials.gov record NCT02305472, source copy `cardio:ctgov-nct02305472-2017-03-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02305472, source copy `cardio:ctgov-nct02305472-2017-03-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02305472-2017-03-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: NeoVas Bioresorbable Coronary Scaffold Registry Study
- Condition: Coronary Artery Disease
- Intervention (Device): NeoVas BCS
- Lead sponsor: Lepu Medical Technology (Beijing) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Lepu Medical Technology (Beijing) Co., Ltd. (`cardio:org-lepu-medical-technology-beijing-co-ltd`)

## Provenance

Content hash: b7ca46cfdc5052ee501fc32f79182b50de782cc68a0c300e82c87b6a531c5083
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
